Chemopreventive efficacy of silymarin in skin and prostate cancer.
Prevention and therapeutic intervention by phytochemicals are newer dimensions in the arena of cancer management. In this regard, the cancer chemopreventive role of silymarin (Silybum marianum) has been extensively studied and has shown anticancer efficacy against various cancer sites, especially skin and prostate. In skin cancer, silymarin treatment inhibits ultraviolet B radiation or chemically initiated or promoted carcinogenesis. These effects of silymarin against skin carcinogenesis have been attributed to its strong antioxidant and anti-inflammatory action as well as its inhibitory effect on mitogenic signaling. Similarly, silymarin treatment inhibits 3, 2-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis and retards the growth of advanced prostate tumor xenograft in athymic nude mice. In prostate cancer, silymarin treatment down-regulates androgen receptor-, epidermal growth factor receptor-, and nuclear factor-kappaB- mediated signaling and induces cell cycle arrest. Extensive preclinical findings have supported the anticancer potential of silymarin, and now its efficacy is being evaluated in cancer patients.
Deep
Gagan
G
Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, CO 80262, USA.
Agarwal
Rajesh
R
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000975:Antioxidants / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002273:Carcinogens / Q000633:toxicity; D002277:Carcinoma / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D018890:Chemoprevention; D002986:Clinical Trials as Topic; D004260:DNA Repair / Q000187:drug effects; D004195:Disease Models, Animal; D066246:ErbB Receptors / Q000502:physiology; D006801:Humans; D008027:Light / Q000009:adverse effects; D008297:Male; D008938:Mitosis / Q000187:drug effects; D008954:Models, Biological; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D012838:Silymarin / Q000494:pharmacology / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D002273:Carcinogens; D012838:Silymarin; C512478:EGFR protein, human; D066246:ErbB Receptors